

DEC 04 2001

PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 11014-24)

11-02  
H.P.

In the Application of:

A. Pedyczak; P. Chong; C.D.Y. Sia )  
Serial No.: 09/829,004 )  
Filed: April 10, 2001 )  
For: Immunogenic Peptides Derived from )  
Prostate-Specific Antigen (PSA) and )  
Uses Thereof )

)  
Examiner: Not Assigned  
)  
Art Unit: 1646  
)

BOX DD  
Asst. Commissioner for Patents  
Washington, DC 20231  
U.S. Express Mail EL667443293US

RECEIVED

DEC 2 0 2001

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Dear Sir/Madam:

We are transmitting herewith the attached:

- 1) Information Disclosure Statement;
- 2) PTO Form 1449;
- 3) Sixty-one (61) references;
- 4) Associate Power of Attorney; and
- 5) Confirmation Postcard.

Applicants do not believe any additional fees are due. However, if this is in error, the undersigned hereby authorizes the Commissioner to charge any deficiency or credit any excess fees to Deposit Account No. 50-0244.


Respectfully submitted,

AVENTIS PASTEUR, INC.

  
\_\_\_\_\_  
Patrick J. Halloran  
Reg. No. 41,053

Date: December 4, 2001

Aventis Pasteur, Inc.  
Patent Department  
Discovery Drive  
Swiftwater, Pennsylvania 18370  
(570) 839-5446 Phone  
(570) 895-2702 Fax



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 11014-24)

In the Application of:

A. Pedyczak; P. Chong; C.D.Y. Sia

Examiner: Not Assigned

Serial No.: 09/829,004

Art Unit: 1646

Filed: April 10, 2001

For: Immunogenic Peptides Derived from  
Prostate-Specific Antigen (PSA) and  
Uses Thereof

TECH CENTER 1600/2900

RECEIVED  
DEC 20 2001

### INFORMATION DISCLOSURE STATEMENT

BOX DD

Asst. Commissioner for Patents  
Washington, D.C. 20231  
U.S. Express Mail EL667443293US

Dear Sir:

Applicants respectfully submit this Information Disclosure Statement, PTO-1449 and copies of the reference cited therein. This Information Disclosure Statement is in compliance with the duty of candor as set forth in 37 C.F.R. § 1.56. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing of the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. §102 or §103.

## CITED REFERENCES

### U.S. Patents

1. 5,034,506
2. 4,598,049
3. 4,458,066
4. 4,401,796
5. 4,373,071
6. 5,843,456
7. 5,283,185

### Foreign Patent Documents

8. WO 79/00475
9. WO 95/17211
10. WO 96/06627
11. WO 95/34323
12. WO 95/02415
13. WO 96/14831
14. WO 88/09336

### Other Documents:

15. Carter, H.B. and Coffey, D.S., *Prostate* (1990) 16:39-48
16. Armbruster, D.A., *Clin Chem* (1993) 39:181-195
17. Wang, M.C., Kuriyama, M., Papsidero, L.D., Loor, R.M., Valenzuela, L.A., Murphy, G.P., and Chu, T.M., *Methods in Cancer Research* (1982) 19:179-197
18. Zietman, A.L., Shipley, W.L., and Willett, C.G., *Cancer* (1993) 71:959-969
19. Boon, T., *Int. J. Cancer* (1993) 54:177-180
20. Yam, *Amer J Med* (1974) 56:604
21. Sharief, F.S., et al., *Biochem Biophys Res Commun* (1992) 184:1468-1476
22. Van Etten, R.L., et al., *J Biol Chem* (1991) 266:9993-9999
23. Sharief, F.S., et al., *Biochem Biophys Res Commun* (1989) 180:79-86


24. Tailor, P.G., et al., *Nucleic Acid Res* (1990) 18:4928
25. Watt, K.W., et al., *Proc Natl Acad Sci USA* (1986) 83:3166-3170
26. Lundwall, A. and Lilja, H., *FEBS Lett* (1987) 214:317-322
27. Schultz, P., et al., *Nucleic Acid Res* (1988) 16:6226
28. Henttu, P. and Bihko, P., *Biochem and Biophys Res Commun* (1989) 1160:903-910
29. Lundwall, A., *Biochem and Biophys Res Commun* (1989) 162:1151-1159
30. Riegman, P.H., et al., *Biochem and Biophys Res Commun* (1989) 159:103-111
31. Klobeck, G., et al., *Nucleic Acid Res* (1989) 17:3981
32. Israeli, R.S., et al., *Cancer Res* (1993) 53:227-230
33. Deres, et al., *Nature* (1989) 342:561-564
34. Loing, et al., *J Immunol* (2000) 164(2):900-907
35. Baier, et al., *Immunobiology* (2000) 201:391-405
36. *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1989) 6.3.1-6.3.6
37. Nielsen, P.E., et al., *Science* (1991) 254:1497
38. Chirgwin, et al., *Biochemistry* (1979) 18:5294-5299
39. Merrifield, *J Am Chem Assoc* (1964) 85:2149-2154
40. Chang, et al., *Nature* (1978) 275:615
41. Nichols and Yanofsky, *Meth in Enzymology* (1983) 101:155
42. Russell, et al., *Gene* (1982) 20:231
43. Bolivar, et al., *Gene* (1977) 2:9S
44. Messing, *Meth in Enzymology* (1983) 101:20-77

45. Vieira and Messing, *Gene* (1982) 19:259-268
46. Amann, et al., *Gene* (1988) 69:301-315
47. Studier, et al., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990) 60-89
48. Baldari, et al., *EMBO J* (1987) 6:229-234
49. Kurjan and Herskowitz, *Cell* (1982) 30:933-943
50. Schultz, et al., *Gene* (1987) 54:113-123
51. Hinnen, et al., *Proc Natl Acad Sci USA* (1978) 75:1929
52. Itoh, et al., *J Bacteriology* (1983) 153:163
53. Cullen, et al., *Bio/Technology* (1987) 5:369
54. Seed, B., *Nature* (1987) 329:840
55. Kaufman, et al., *EMBO J* (1987) 6:187-195
56. Sinkar, et al., *J Biosci (Bangalore)* (1987) 11:47-58
57. Smith, et al., *Mol Cell Biol* (1983) 3:2156-2165
58. Lucklow, V.A. and Summers, M.D., *Virology* (1989) 170:31-39
59. Salter, R.D. and Creswel, P., *EMBO J* (1986) 5:943
60. Deng, Y., *Immunol* (1997) 158:1507-1515
61. Milich, D.R., et al., *J Immunol* (1987) 139:1223-1231

Respectfully Submitted,  
AVENTIS PASTEUR INC.

Date: December 4, 2001

By:

  
\_\_\_\_\_  
Patrick J. Halloran  
Reg. No. 41,053